Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

By J. Bisognano, G. Bakris, M. Nadim, L. Sanchez, A. Kroon, J. Schafer, P. D. de Leeuw, D. Sica. Journal of the American College of Cardiology, 2011

619 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Neurology

View Paper: https://www.semanticscholar.org/paper/e67415ca309a06fc88d9a1a508450114dba6af54

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Philippe van de Borne
2. H. S. Boudier

Citations in the corpus

• Diabetic Kidney Disease: A Report From an ADA Consensus Conference (2014, neutral): “Baroreflex activation therapy shows promise but is still experimental and under development (60).”
• ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “implanted devices has recently been reported to reduce SBP and DBP in resistant hypertensive individuals.(614) – 616 The reduction was”